Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II
Filament HealthNEO: FH | OTCQB: FLHLF | FSE: 7QS
3 Drug Candidates3 Trials
Filament Health is a Canadian clinical-stage natural psychedelic drug development company focused on botanical psilocybin formulations. Their proprietary botanical drug product PEX010 — a standardised whole-psilocybin mushroom extract — has been authorised for investigation in over 50 clinical trials worldwide. The company's strategy centres on developing a natural medicine approved by health authorities, with active Phase 2 programmes across substance use disorders including alcohol, opioid, and stimulant use disorder.
Drug Pipeline
3Phase II
Alcohol Use Disorder (AUD)
Phase II
Opioid Use Disorder (OUD)
Phase II
Methamphetamine / Stimulant Use Disorder (MAUD)
Quick Facts
- Type
- Public Biotech
- Ticker
- NEO: FH | OTCQB: FLHLF | FSE: 7QS
- Lead Stage
- Phase II
- Website
- Visit